121 related articles for article (PubMed ID: 10429421)
1. [Limitations on the interpretation of prostate-specific antigen serum levels].
Sciarra A; Casale P; Di Nicola S; Di Chiro C; Colella D; Di Silverio F
Minerva Urol Nefrol; 1999 Jun; 51(2):105-12. PubMed ID: 10429421
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW; Hanks GE; Klein EA; Moul JW; Nelson WG; Scher HI
Oncology (Williston Park); 2002 Sep; 16(9):1218-24; discussion 1224, 1227-8 passim. PubMed ID: 12380948
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer update: 2005.
Ryan CJ; Small EJ
Curr Opin Oncol; 2006 May; 18(3):284-8. PubMed ID: 16552242
[TBL] [Abstract][Full Text] [Related]
4. The role of prostate-specific antigen in light of new scientific evidence.
Hernández C; Morote J; Miñana B; Cózar JM
Actas Urol Esp; 2013 Jun; 37(6):324-9. PubMed ID: 23608183
[TBL] [Abstract][Full Text] [Related]
5. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
6. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
7. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
8. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
9. Update on the diagnosis and treatment of prostate cancer.
Small EJ
Curr Opin Oncol; 1998 May; 10(3):244-52. PubMed ID: 9619361
[TBL] [Abstract][Full Text] [Related]
10. [Possible value of positive PSA levels in malignant and nonmalignant breast diseases].
Schuff-Werner P; Zingler C
Onkologie; 2001 Feb; 24 Suppl 1():11-7. PubMed ID: 11441307
[TBL] [Abstract][Full Text] [Related]
11. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.
Morote J; Trilla E; Esquena S; Abascal JM; Reventos J
Int J Cancer; 2004 Mar; 108(6):877-81. PubMed ID: 14712491
[TBL] [Abstract][Full Text] [Related]
12. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
McGivern U; Mitchell DM; McDowell C; O'Hare J; Corey G; O'Sullivan JM
Clin Genitourin Cancer; 2012 Sep; 10(3):190-5. PubMed ID: 22677511
[TBL] [Abstract][Full Text] [Related]
15. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
18. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on prostate cancer diagnosis and treatment: a roundtable.
Brawer MK; Stamey TA; Fowler J; Droller M; Messing E; Fair WR
Urology; 2001 Aug; 58(2):135-40. PubMed ID: 11489681
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
